Azemiglitazone
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2011 (NCT01280695)
Timeline
Indications
Mechanism of action
- Mitochondrial pyruvate carrier 1INHIBITOR
MPC1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- msdc-0602
- msdc-0602
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07186660 | Phase 2 | Oct 15, 2025 | University of Virginia |
| NCT03970031 | Phase 3 | Sep 30, 2019 | Cirius Therapeutics, Inc. |
| NCT02784444 | Phase 2 | Jul 1, 2016 | Chiltern International, Cirius Therapeutics, Inc. |
| NCT01280695 | Phase 2 | Feb 1, 2011 | Metabolic Solutions Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cirius Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2016 |
| Chiltern International | For profit | 1 | 0 | 1 | 2016 |
| Metabolic Solutions Inc. | For profit | 1 | 1 | 1 | 2011 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1